Related Experiment Video
Updated: May 8, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Combination therapy in metastatic renal cell cancer
Alain Ravaud1, Marine Gross-Goupil, Joaquim Bellmunt
1Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France. alain.ravaud@chu-bordeaux.fr
Seminars in Oncology
|August 27, 2013
Summary
Sequential treatment is standard for metastatic renal cell carcinoma (mRCC). While targeted drug combinations show theoretical promise for mRCC, clinical benefit remains unproven, and increased toxicity is a concern.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment typically involves sequential therapies.
- Multiple pathways contribute to mRCC pathogenesis and drug resistance.
- Targeted drug combinations offer theoretical advantages in inhibiting key pathways or overcoming resistance mechanisms.
Purpose of the Study:
- To review the current evidence for combination targeted therapy in mRCC.
- To discuss the potential benefits and challenges of combining targeted agents.
- To highlight ongoing research into novel targeted drug combinations for mRCC.
Main Methods:
- Review of existing clinical trial data and preclinical studies on targeted therapy combinations in mRCC.
- Analysis of pathway involvement in mRCC and drug resistance.
- Evaluation of toxicity profiles associated with combination regimens.
Main Results:
- Combinations of vascular endothelial growth factor (VEGF) inhibitors and mammalian target of rapamycin (mTOR) inhibitors have been most studied.
- Newer generation VEGF tyrosine kinase inhibitors (TKIs) may offer improved tolerability for combination therapy.
- Evidence for clear clinical benefit of combination therapy in mRCC is currently lacking, with observed excess toxicity.
Conclusions:
- Combination targeted therapy in mRCC presents theoretical advantages but lacks definitive clinical validation.
- Careful consideration of drug interactions and toxicity is crucial when exploring combination strategies.
- Ongoing trials investigating PI3K/akt/mTORC1/2 inhibitors and other novel agents are critical for future treatment advancements in mRCC.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...